High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study

Journal of Clinical Lipidology

Volumn 9, Issue 4, 2015, Pages 553-558

  Hashemi Nazari, Seyed Saeed ^a   Shakiba, Maryam ^b   Khalili, Davood ^c   Hadaegh, Farzad ^c   Tohidi, Maryam ^c   Azizi, Fereidoun ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coronary heart disease; Cox proportional hazard model; High density lipoprotein cholesterol; Menopause; Time varying model

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CORONARY DISEASE; IRAN; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; AGED; CORONARY DISEASE; FEMALE; GLUCOSE; HUMANS; IRAN; LIPOPROTEINS, HDL; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS; TRIGLYCERIDES;

EID: 84938199976     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.04.001     Document Type: Article

References (31)

1. M.J. McQueen, S. Hawken, X. Wang, and et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries: a case-control study Lancet 372 2008 224 233
2. B.F. Voight, G.M. Peloso, M. Orho-Melander, and et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian Randomisation Study Lancet 380 9841 2012 572 580
3. C.L. Haase, A. Tybjaerg-Hansen, P. Grande, and R. Frikke-Schmidt Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease J Clin Endocrinol Metab 95 12 2010 E500 E510
4. C.L. Haase, A. Tybjaerg-Hansen, A.A. Qayyum, J. Schou, B.G. Nordestgaard, and R. Frikke-Schmidt LCAT, HDL cholesterol and ischemic cardiovasculardisease: a Mendelian Randomization Study of HDL cholesterol in 54,500 individuals J Clin Endocrinol Metab 97 2012 E248 E256
5. P.M. Ridker, J. Genest, S.M. Boekholdt, and et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 9738 2010 333 339
6. P.P. Toth, M. Barylski, D. Nikolic, M. Rizzo, G. Montalto, and M. Banach Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab 28 3 2014 353 368
7. M. Barylski, P.P. Toth, D. Nikolic, M. Banach, M. Rizzo, and G. Montalto Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality Best Pract Res Clin Endocrinol Metab 28 3 2014 Jun 453 461
8. M. Rizzo, J. Otvos, D. Nikolic, G. Montalto, P.P. Toth, and M. Banach Subfractions and subpopulations of HDL: an update Curr Med Chem 21 25 2014 2881 2891
9. S.S. Martin, S.R. Jones, and P.P. Toth High-density lipoprotein subfractions: current views and clinical practice applications Trends Endocrinol Metab 25 7 2014 329 336
10. S. Dragan, C. Serban, and M. Banach Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents? Curr Med Chem 21 25 2014 2927 2946
11. G. Marsche, M.D. Saemann, A. Heinemann, and M. Holzer Inflammation alters HDL composition and function: implications for HDL-raising therapies Pharmacol Ther 137 2013 341 351
12. M. Holzer, M. Trieb, V. Konya, C. Wadsack, A. Heinemann, and G. Marsche Aging affects high-density lipoprotein composition and function Biochim Biophys Acta 1831 9 2013 1442 1448
13. M. Holzer, R. Birner-Gruenberger, T. Stojakovic, and et al. Uremia alters HDL composition and function J Am Soc Nephrol 22 9 2011 1631 1641
14. M. Holzer, P. Wolf, S. Curcic, and et al. Psoriasis alters HDL composition and cholesterol efflux capacity J Lipid Res 53 8 2012 1618 1624
15. M. Banach Editorial: Current research, knowledge and controversies on high density lipoprotein Curr Med Chem 21 25 2014 2853 2854
16. M. Tohidi, M. Hatami, F. Hadaegh, M. Safarkhani, H. Harati, and F. Azizi Lipid measures for prediction of incident cardiovascular disease in diabetic and nondiabetic adults: results of the 8.6 years follow-up of a population based cohort study Lipids Health Dis 9 2010 6
17. F. Azizi, M. Rahmani, H. Emami, and et al. Cardiovascular risk factors in an Iranian urban population: Tehran Lipid and Glucose Study (phase 1) Soz Praventivmed 47 6 2002 408 426
18. F. Azizi, A. Ghanbarian, A.A. Momenan, and et al. Prevention of non-communicable disease in population in nutrition transition: Tehran Lipid and Glucose Study phase II Trials 10 2009 5
19. M. Farahmand, F.R. Tehrani, L. Pourrajabi, M. Najafi, and F. Azizi Factors associated with menopausal age in Iranian women: Tehran Lipid and Glucose Study J Obstet Gynaecol Res 39 4 2013 836 841
20. M.J. Pencina, M.G. Larson, and R.B. D'Agostino Choice of time scale and its effect on significance of predictors in longitudinal studies Stat Med 26 6 2007 1343 1359
21. A. Onat, G. Can, E. Ayhan, Z. Kaya, and G. Hergenc Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks Metabolism 58 2009 1393 1399
22. U. Landmesser, A. von Eckardstein, J. Kastelein, J. Deanfield, and T.F. Luscher Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme Eur Heart J 33 2012 1712 1715
23. A. Otocka-Kmiecik, D.P. Mikhailidis, S.J. Nicholls, M. Davidson, J. Rysz, and M. Banach Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51 4 2012 314 324
24. W. Fendler, M. Rizzo, M. Borowiec, and et al. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level Acta Diabetol 51 4 2014 625 632
25. M.K. Jensen, E.B. Rimm, J.D. Furtado, and F.M. Sacks Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease J Am Heart Assoc 1 2 2012 10.1161/JAHA.111.000232
26. A. Noma, Y. Hata, and Y. Goto Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences Clin Chim Acta 199 2 1991 147 157
27. A.S. Foulkes, D.A. Wohl, I. Frank, and et al. Association among race/ethnicity, ApoC-III genotype, and lipids in HIV-1 infected individuals on antiretroviral therapy PLoS Med 3 3 2006 e52
28. S. Dodani, R. Kaur, S. Reddy, G.L. Reed, and N. Mohammad Can dysfunctional HDL explain high coronary artery disease risk in South Asians? Int J Cardiol 129 1 2008 125 132
29. N.C. Bhalodkar, S. Blum, T. Rana, and et al. Comparison of levels of large and small high-density lipoprotein cholesterol in Asian Indian men compared to Caucasian men in the Framingham Offspring Study Am J Cardiol 94 12 2004 1561 1563
30. S. Dodani, L. Dong, F.W. Guirgis, and S.T. Reddy Carotid intima media thickness and low high-density lipoprotein (HDL) in South Asian immigrants: could dysfunctional HDL be the missing link? Arch Med Sci 10 5 2014 870 879
31. R. Clarke, M. Shipley, S. Lewington, and et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies Am J Epidemiol 150 4 1999 341 353